Pfizer Corporation

Aptinyx Inc.

Alkermes, Inc.

Rodin Therapeutics, Inc.

Alkermes Pharma Ireland Limited

Other

Agenebio, Inc.

Cadent Therapeutics, Inc.

Tenacia Biotechnology (hong Kong) Co., Limited

Apytinyx Inc.

John Adams Lowe, Iii

M Amin Khan

Nathan Oliver Fuller

Terry J Rosen

Fumitaka Ito

Hiroshi Kondo

Martin R Jefson

Masami Nakane

Laura Cook Blumberg

Tarek A Zeidan

Arthur A Nagel

Fabian Dey

Orn Almarsson

Juan C Alvarez

Manoj C Desai

Kaoru Shimada

Andreas Schoop

Andreas Bergmann

Stanton F McHardy

Peter J Whittle

Katherine E Brighty

Paul R McGuirk

Terry Jay Rosen

Steven Wayne Goldstein

Robert A Volkmann

Brian Thomas O'Neill

John Michael McCall

Jennifer Elizabeth Davoren

Harry R Howard, Jr

Birgitte Langer Eriksen

Gregg F Keaney

Kunio Satake

Janus Schreiber Larsen

Mark Allen Sanner

Fredric J Vinick

Susumu Nakanishi

Charlotte Hougaard

Dorte Strøbæk

Masaya Ikunaka

Magnus Gustafsson

Thomas Amos Jacobsen

David L Hageman

Michelle Marie Claffey

Kelly P Longo

John W Watson

Hans J Hess

Giovanni Piedimonte

Robert B Nelson

Jessica Klein

Nadia Lybøl Von Schoubye

Robert Joseph Mather

Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

Spiro-lactam NMDA receptor modulators and uses thereof

Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2). The compounds are bicyclic inhibitors of histone deacetylase, useful for treating neurological disorders, memory or cognitive function disorders or impairments, extinction learning disorders, fungal diseases or infections, inflammatory diseases, hematological diseases, neoplastic diseases, psychiatric disorders, and memory loss.

Bicyclic inhibitors of histone deacetylase

Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).

Substituted pyridines as inhibitors of histone deacetylase

This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula I, II or any of Compounds 100-128 or any of those in Tables 2 or 3) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Hetero-halo inhibitors of histone deacetylase

Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g., HDAC2).

The present invention relates to compounds of Formula I: 

Prodrugs of secondary amine compounds

Provided are compounds of the formula and pharmaceutically acceptable salts and composition thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g. HDAC2).

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels. 

Potassium channel modulators

Growing community of inventors

Stonington, CT, United States of America

John Adams Lowe, Iii